1Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative. Am J Cardiovasc Drugs,2003,3:169-178.
2Snow V, Aronson MD, Hornbake ER, et al. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med,2004,140: 644-649.
3American diabetes association. Dyslipidemia management in adults with diabetes. Diabetes Care,2004,27(Suppl): S68-S71.
4Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation,2002,106: 1024-1028.
5Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol,1997,80: 106- 107.
6Pauciullo P, Borgnino C, Paoletti R, et al. Effcacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis,2000,150: 429-436.
7Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J cardiol,2003,91: 956-960.
8Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Cin Invest,2001,107:1423-1432.
9Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett,2002,128:159-168.
10Davidson MH. Combination Therapy for Dyslipidemia: Safety and Regulatory Considerations,Am J Cardiol,2002,90(Suppl): 50K-60K.
